Zhang Bao

机构：Zero to Three, First Affiliated Hospital Zhejiang University · ORCID：0000-0002-3057-1109

发表论文 140 篇 · 总被引 2336 次 · h-index 29

代表论文

• Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial (2021 · Signal Transduction and Targeted Therapy · 被引 95)
• Phosphorylation of ATG18a by BAK1 suppresses autophagy and attenuates plant resistance against necrotrophic pathogens (2020 · Autophagy · 被引 82)
• Leaching kinetics and interface reaction of LiNi0.6Co0.2Mn0.2O2 materials from spent LIBs using GKB as reductant (2021 · Journal of Environmental Management · 被引 63)
• The PGC1α/NRF1-MPC1 axis suppresses tumor progression and enhances the sensitivity to sorafenib/doxorubicin treatment in hepatocellular carcinoma (2020 · Free Radical Biology and Medicine · 被引 57)
• Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients (2021 · Cancer Immunology Immunotherapy · 被引 44)
• Repurposing clinically approved drugs for COVID-19 treatment targeting SARS-CoV-2 papain-like protease (2021 · International Journal of Biological Macromolecules · 被引 43)